巨細胞性動脈炎(GCA)の疫学予測(~2028)

◆英語タイトル:Giant Cell Arteritis (GCA) Epidemiology Forecast-2028
◆商品コード:DATA00109019
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥373,750見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,121,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Giant Cell Arteritis (GCA) Epidemiology Forecast-2028
DelveInsight’s ‘Giant Cell Arteritis (GCA)- Epidemiology Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of GCA in the 7 Major Markets (MM) i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028

Giant Cell Arteritis (GCA) – Disease Understanding

The DelveInsight Giant Cell Arteritis epidemiology report gives the thorough understanding of the GCA by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Giant Cell Arteritis in the 7 Major Markets (MM), i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. Giant cell arteritis (GCA) is an inflammatory disorder of medium- and large-size arteries affecting older people. Classically involved vascular sites include the external carotid branches, the ophthalmic, vertebral, distal subclavian, and axillary arteries as well as the aorta.

Giant Cell Arteritis (GCA) Epidemiology

The Giant Cell Arteritis (GCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major markets. The epidemiology data for Giant Cell Arteritis epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Giant Cell Arteritis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Giant Cell Arteritis in 7MM, Sub-type specific prevalence of Giant Cell Arteritis, Gender Specific Diagnosed prevalence of Giant Cell Arteritis, Age Specific Diagnosed prevalence of Giant Cell Arteritis, Clinical Manifestations associated with Giant Cell Arteritis) scenario of Giant Cell Arteritis(GCA) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, Total prevalent population of Giant Cell Arteritis in 7 MM was observed to be 423,131 cases in 2017.

Report Scope

• The report covers the descriptive overview of Giant Cell Arteritis , explaining its causes and currently available therapies
• Comprehensive insight has been provided into the epidemiology of the Giant Cell Arteritis and its treatment in the 7 MM.
• A detailed review of global historical and forecasted Giant Cell Arteritis epidemiology is included in the report, covering drug all 7 MM.

Giant Cell Arteritis Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Giant Cell Arteritis Epidemiology Segmentation

• Total prevalence of Giant Cell Arteritis in 7 MM
• Sub-type specific prevalence of Giant Cell Arteritis in 7 MM
• Gender Specific Diagnosed prevalence of Giant Cell Arteritis in 7 MM
• Age Specific Diagnosed prevalence of Giant Cell Arteritis in 7 MM
• Clinical Manifestations of Giant Cell Arteritis in 7 MM

Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report.

【レポートの目次】

1. Key Insights
2. Giant cell arteritis Market Overview at a Glance
2.1. Market Share (%) of Giant cell arteritis in 2017 – 7MM
2.2. Market Share (%) of Giant cell arteritis in 2028 – 7MM
3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and risk factors
3.3. Signs and Symptoms associated with GCA
3.4. Pathophysiology
3.5. Clinical manifestations
3.6. Diagnosis
3.7. Molecular biomarkers in GCA patients important for diagnosis and prognosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Cases of Giant Cell Arteritis in 7MM
5. Country Wise-Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of Giant Cell Arteritis in the United States
5.1.3. Sub-type specific prevalence of GCA in the United States
5.1.4. Gender Specific Diagnosed prevalence of GCA in the United States
5.1.5. Age Specific Diagnosed prevalence of GCA in the United States
5.1.6. Clinical Manifestations associated with GCA in the United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
5.3.1. Assumptions and Rationale
5.3.2. Prevalence of Giant Cell Arteritis in Japan
5.3.3. Sub-type specific prevalence of GCA in Japan
5.3.4. Gender Specific Diagnosed prevalence of GCA in Japan
5.3.5. Age Specific Diagnosed prevalence of GCA in Japan
5.3.6. Clinical Manifestations associated with GCA in Japan
6. Treatment and Management
6.1. The new era for GCA: Biologic Agents
6.2. Patient Journey
7. Unmet needs
8. Appendix
8.1. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Table 1: Total Prevalent Population of GCA in 7MM (2017-2028)
Table 2: Prevalent Cases of GCA in the United States (2017-2028)
Table 3: Sub-type specific prevalent cases of GCA in the United States (2017-2028)
Table 4: Gender Specific Diagnosed Prevalence of GCA in the United States (2017-2028)
Table 5: Age Specific Diagnosed prevalence of GCA in the United States (2017-2028)
Table 6: Clinical Manifestations associated with GCA in the United States (2017-2028)
Table 7: Prevalent Cases of GCA in Germany (2017-2028)
Table 8: Sub-type specific prevalent cases of GCA in Germany (2017-2028)
Table 9: Gender Specific Diagnosed Prevalence of GCA in Germany (2017-2028)
Table 10: Age Specific Diagnosed prevalence of GCA in Germany (2017-2028)
Table 11: Clinical Manifestations associated with GCA in Germany (2017-2028)
Table 12: Prevalent Cases of GCA in France (2017-2028)
Table 13: Sub-type specific prevalent cases of GCA in France (2017-2028)
Table 14: Gender Specific Diagnosed Prevalence of GCA in France (2017-2028)
Table 15: Age Specific Diagnosed prevalence of GCA in France (2017-2028)
Table 16: Clinical Manifestations associated with GCA in France (2017-2028)
Table 17: Prevalent Cases of GCA in Italy (2017-2028)
Table 18: Sub-type specific prevalent cases of GCA in Italy (2017-2028)
Table 19: Gender Specific Diagnosed Prevalence of GCA in Italy (2017-2028)
Table 20: Age Specific Diagnosed prevalence of GCA in Italy (2017-2028)
Table 21: Clinical Manifestations associated with GCA in Italy (2017-2028)
Table 22: Prevalent Cases of GCA in Spain (2017-2028)
Table 23: Sub-type specific prevalent cases of GCA in Spain (2017-2028)
Table 24: Gender Specific Diagnosed Prevalence of GCA in Spain (2017-2028)
Table 25: Age Specific Diagnosed prevalence of GCA in Spain (2017-2028)
Table 26: Clinical Manifestations associated with GCA in Spain (2017-2028)
Table 27: Prevalent Cases of GCA in UK (2017-2028)
Table 28: Sub-type specific prevalent cases of GCA in UK (2017-2028)
Table 29: Gender Specific Diagnosed Prevalence of GCA in UK (2017-2028)
Table 30: Age Specific Diagnosed prevalence of GCA in UK (2017-2028)
Table 31: Clinical Manifestations associated with GCA in UK (2017-2028)
Table 32: Prevalent Cases of GCA in Japan (2017-2028)
Table 33: Sub-type specific prevalent cases of GCA in Japan (2017-2028)
Table 34: Gender Specific Diagnosed Prevalence of GCA in Japan (2017-2028)
Table 35: Age Specific Diagnosed prevalence of GCA in Japan (2017-2028)
Table 36: Clinical Manifestations associated with GCA in Japan (2017-2028)
Figure 1: Common symptoms associated with GCA
Figure 2: Main pathways involved in the immunopathology of giant cell arteritis
Figure 3: Proposed algorithm for evaluating patients with suspected GCA
Figure 4: Total Prevalent Population of GCA in 7 MM (2017-2028)
Figure 5: Prevalent Population of GCA in the United States (2017-2028)
Figure 6: Sub-type specific prevalent cases of GCA in the United States (2017-2028)
Figure 7: Gender Specific Diagnosed Prevalence of GCA in the United States (2017-2028)
Figure 8: Age Specific Diagnosed prevalence of GCA in the United States (2017-2028)
Figure 9: Clinical Manifestations associated with GCA in the United States (2017-2028)
Figure 10: Prevalent Population of GCA in Germany (2017-2028)
Figure 11: Sub-type specific prevalent cases of GCA in Germany (2017-2028)
Figure 12: Gender Specific Diagnosed Prevalence of GCA in Germany (2017-2028)
Figure 13: Age Specific Diagnosed prevalence of GCA in Germany (2017-2028)
Figure 14: Clinical Manifestations associated with GCA in Germany (2017-2028)
Figure 15: Prevalent Population of GCA in France (2017-2028)
Figure 16: Sub-type specific prevalent cases of GCA in France (2017-2028)
Figure 17: Gender Specific Diagnosed Prevalence of GCA in France (2017-2028)
Figure 18: Age Specific Diagnosed prevalence of GCA in France (2017-2028)
Figure 19: Clinical Manifestations associated with GCA in France (2017-2028)
Figure 20: Prevalent Population of GCA in Italy (2017-2028)
Figure 21: Sub-type specific prevalent cases of GCA in Italy (2017-2028)
Figure 22: Gender Specific Diagnosed Prevalence of GCA in Italy (2017-2028)
Figure 23: Age Specific Diagnosed prevalence of GCA in Italy (2017-2028)
Figure 24: Clinical Manifestations associated with GCA in Italy (2017-2028)
Figure 25: Prevalent Population of GCA in Spain (2017-2028)
Figure 26: Sub-type specific prevalent cases of GCA in Spain (2017-2028)
Figure 27: Gender Specific Diagnosed Prevalence of GCA in Spain (2017-2028)
Figure 28: Age Specific Diagnosed prevalence of GCA in Spain (2017-2028)
Figure 29: Clinical Manifestations associated with GCA in Spain (2017-2028)
Figure 30: Prevalent Population of GCA in UK (2017-2028)
Figure 31: Sub-type specific prevalent cases of GCA in UK (2017-2028)
Figure 32: Gender Specific Diagnosed Prevalence of GCA in UK (2017-2028)
Figure 33: Age Specific Diagnosed prevalence of GCA in UK (2017-2028)
Figure 34: Clinical Manifestations associated with GCA in UK (2017-2028)
Figure 35: Prevalent Population of GCA in Japan (2017-2028)
Figure 36: Sub-type specific prevalent cases of GCA in Japan (2017-2028)
Figure 37: Gender Specific Diagnosed Prevalence of GCA in Japan (2017-2028)
Figure 38: Age Specific Diagnosed prevalence of GCA in Japan (2017-2028)
Figure 39: Clinical Manifestations associated with GCA in Japan (2017-2028)
Figure 40: Current treatment schema for GCA
Figure 41:Management of Giant Cell Arteritis (GCA)
Figure 42: Patient Journey for GCA
Figure 43: Unmet needs for GCA



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[巨細胞性動脈炎(GCA)の疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆